Focused On-demand Library for Protein FRG1

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

The focused library is created on demand with the latest virtual screening and parameter assessment technology, supported by the Receptor.AI drug discovery platform. This method is more effective than traditional methods and results in higher-quality compounds with better activity, selectivity, and safety.

The compounds are cherry-picked from the vast virtual chemical space of over 60B molecules. The synthesis and delivery of compounds is facilitated by our partner Reaxense.

In the library, a selection of top modulators is provided, each marked with 38 ADME-Tox and 32 parameters related to physicochemical properties and drug-likeness. Also, every compound comes with its best docking poses, affinity scores, and activity scores, providing a comprehensive overview.

Our high-tech, dedicated method is applied to construct targeted libraries.

Fig. 1. The sreening workflow of Receptor.AI

Our methodology employs molecular simulations to explore a wide array of proteins, capturing their dynamic states both individually and within complexes. Through ensemble virtual screening, we address conformational mobility, uncovering binding sites within functional regions and remote allosteric locations. This thorough exploration ensures no potential mechanism of action is overlooked, aiming to discover novel therapeutic targets and lead compounds across an extensive spectrum of biological functions.

Several key aspects differentiate our library:

Receptor.AI compiles an all-encompassing dataset on the target protein, including historical experiments, literature data, known ligands, and structural insights, maximising the chances of prioritising the most pertinent compounds.
The platform employs state-of-the-art molecular simulations to identify potential binding sites, ensuring the focused library is primed for discovering allosteric inhibitors and binders of concealed pockets.
Over 50 customisable AI models, thoroughly evaluated in various drug discovery endeavours and research projects, make Receptor.AI both efficient and accurate. This technology is integral to the development of our focused libraries.
In addition to generating focused libraries, Receptor.AI offers a full range of services and solutions for every step of preclinical drug discovery, with a pricing model based on success, thereby reducing risk and promoting joint project success.

partner

Reaxense

upacc

Q14331

UPID:

FRG1_HUMAN

Alternative names:

FSHD region gene 1 protein

Alternative UPACC:

Q14331; A8K775

Background:

Protein FRG1, also known as FSHD region gene 1 protein, plays a crucial role in various cellular processes. It binds to mRNA in a sequence-independent manner, influencing pre-mRNA splicing, rRNA assembly into ribosomal subunits, mRNA transport, and epigenetic regulation of muscle differentiation. Its involvement in these processes underscores its importance in cellular function and gene expression regulation.

Therapeutic significance:

The protein's link to Facioscapulohumeral muscular dystrophy 1 (FSHD1), a degenerative muscle disease, highlights its therapeutic significance. Overexpression of FRG1 leads to FSHD1-like symptoms, including muscle dystrophy and atrophy. Understanding FRG1's role could pave the way for novel therapeutic strategies targeting its overexpression and the resultant aberrant splicing, offering hope for FSHD1 patients.